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Purpose: Sublingual buprenorphine and combina-
tion buprenorphine/naloxone (BNX) are effective op-
tions for the treatment of opioid dependence. A BNX
sublingual tablet approved by the US Food and Drug
Administration for the induction and maintenance
treatment of opioid-dependence in adults was devel-
oped as a higher-bioavailability formulation, allowing
for a 30% lesser dose of buprenorphine with bioequi-
valent systemic exposure compared with another BNX
sublingual tablet formulation. No data were previously
available comparing the higher-bioavailability BNX
sublingual tablet to generic buprenorphine or BNX
sublingual ﬁlm; we therefore evaluated treatment re-
tention during induction and stabilization with the
higher-bioavailability BNX sublingual tablet versus
generic buprenorphine or BNX sublingual ﬁlm.
Methods: This multicenter, prospective, random-
ized, parallel-group noninferiority trial was conducted
at 43 centers in the United States. Eligible patients
were adults aged 18 to 65 years who met the criteria
for opioid dependence and had at least mild with-
drawal symptoms. On days 1 and 2, patients received
blinded, ﬁxed-dose induction with the higher-
bioavailability BNX sublingual tablet or generic bu-
prenorphine. On days 3 to 14, patients induced with
BNX received open-label, titrated doses of the BNX
tablet for stabilization; patients induced with bupre-
norphine received sublingual BNX ﬁlm. Co-primary
end points were treatment retention on days 3 and 15;
noninferiority was concluded if the lower limit of the
95% CI of the between-group difference in treatment*The 006 Study Investigators are listed in the Acknowledgments.
2244retention was Z10%. Tolerability was assessed
throughout the study period.
Findings: A total of 758 opioid-dependent patients
were included in the study (BNX sublingual tablet, 383
patients; generic buprenorphine, 375). Day-3 retention
rates were 93.9% (309/329) and 92.6% (302/326) with
the BNX tablet and buprenorphine, respectively (be-
tween-group difference 95% CI, 2.6 to 5.1). Day-15
retention rates were 83.0% (273/329) and 82.5% (269/
326) with the BNX tablet and BNX ﬁlm, respectively
(between-group difference 95% CI, –5.3 to 6.3). No
unexpected tolerability issues were identiﬁed; the safety
proﬁle of the BNX sublingual tablet was similar to those
of generic buprenorphine and BNX ﬁlm.
Implications: Based on the ﬁndings from this study
in patients with opioid dependence, the higher-
bioavailability BNX sublingual tablet formulation
was noninferior to both generic buprenorphine (in-
duction) and BNX ﬁlm (stabilization). These ﬁndings
suggest that BNX sublingual tablets are an efﬁcacious
and well-tolerated option for induction and early
stabilization treatment of opioid dependence. Clini-
calTrials.gov identiﬁer: NCT01908842. (Clin Ther.
2015;37:2244–2255) & 2015 The Authors. Published
by Elsevier HS Journals, Inc.
Key words: buprenorphine, buprenorphine/nalox-
one combination, induction therapy, maintenance
therapy, treatment retention.0149-2918/$ - see front matter
& 2015 The Authors. Published by Elsevier HS Journals, Inc. This is an
open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Sublingual buprenorphine and combination buprenor-
phine/naloxone (BNX) are effective options for ofﬁce-
based treatment of opioid dependence.1,2 Buprenor-
phine is a partial m-opioid receptor agonist that
promotes treatment retention, reduces illicit drug
use, and relieves cravings in patients dependent on
full m-opioid agonists.3 Unlike other partial opioid
agonists, buprenorphine binds with high afﬁnity to the
m-opioid receptor.4 From a clinical perspective, the
tight binding blocks the effects of exogenous opioids,
which is important for the prevention of relapse.
However, displacement of full m-opioids by the
higher-afﬁnity partial agonist can lead to precipitated
withdrawal,5,6 which poses a clinical challenge during
induction as patients transition from full m-opioids.
The m-receptor antagonist naloxone is included in
combination products to deter abuse, as it precipitates
withdrawal symptoms when taken parenterally by
opioid-dependent patients.7,8 Naloxone has no or
limited systemic effects when administered sublin-
gually due to its low bioavailability via this route.4
The use of a BNX sublingual tablet formulation* was
approved in 2002 by the US Food and Drug
Administration for the treatment of opioid depen-
dence in adults. Although the branded product was
discontinued from the market, generic formulations
remain available. Subsequently, a sublingual BNX ﬁlm
formulation† was approved in 2010 for use as
maintenance treatment of opioid dependence in adults
and in 2014 for the induction of treatment in those
transitioning from short-acting opioids.9,10 No BNX
formulation is licensed for induction therapy in both
patients dependent on long-acting opioids and patients
dependent on short-acting opioids. The induction of
therapy in patients dependent on long-acting opioids (eg,
methadone) might be complicated by an increased risk
for precipitated or prolonged withdrawal.11–13 Limited
clinical evidence exists regarding the efﬁcacy of BNX
ﬁlm for induction in patients dependent on long-acting
opioids, or among those transitioning from long-acting
extended-release preparations.14,15 Thus, buprenorphine
monotherapy is the only treatment approved and
recommended11 for induction in patients transitioning
from long-acting opioids. After successful induction,*Trademark: Suboxones (Reckitt Benckiser, Richmond,
Virginia).
†Trademark: Suboxones sublingual ﬁlm (Reckitt Benckiser).
October 2015adherence of opioid-dependent patients to maintenance
BNX therapy is important for preventing relapse and
future illicit opioid use.16 In addition, successful
maintenance therapy might integrate psychosocial
treatment to promote behavioral and/or lifestyle
changes, as well as to address psychosocial challenges
that might contribute to a patient’s addiction.9,11
A higher-bioavailability BNX sublingual tablet for-
mulation‡ was approved by the FDA in July 2013 for
use as maintenance treatment in adult patients with
opioid dependence and was made available for clinical
use in September 2013. An indication for induction
treatment in adult patients with opioid dependence
followed in August 2015. This higher-bioavailability
BNX sublingual product allows for the administration
of a 30% lesser dose of buprenorphine with systemic
exposure (ie, bioavailability) equivalent to that of a
previously available BNX sublingual tablet formulation;
the development of this tablet formulation also incor-
porated speciﬁc characteristics to address patients’
preferences.9 The technology used in the formulation,
comprising micronized buprenorphine in an associative
admixture with a citric acid buffer system, demonstrates
rapid disintegration, an immediate but temporary
reduction in pH, and synchronized buprenorphine re-
lease in vitro. These properties contribute to its increa-
sed dissolution rate and improved bioavailability.17
The clinical development of this higher-
bioavailability sublingual tablet focused initially on
comparisons to the previously available BNX tablet
formulation. In a comparative bioavailability study in
healthy participants who received naltrexone blockade,
the use of a 5.7/1.4 mg dose of the BNX sublingual
tablet (a 30% lesser buprenorphine dose) maintained
bioequivalent buprenorphine systemic exposure9 and
12% less naloxone exposure,17 as well as signiﬁcantly
faster sublingual dissolve time (P o 0.0001),9
compared with those of the other, 8/2-mg, BNX tablet.
Although these pharmacokinetic data on the
higher-bioavailability BNX sublingual tablet9 were
sufﬁcient for FDA approval, no published clinical
studies have compared the effects of the BNX
sublingual tablet formulation with either the generic
buprenorphine sublingual tablet or BNX sublingual
ﬁlm. Given the importance of such data for guiding
physicians’ and patients’ decision making, the clinical‡Trademark: Zubsolvs (Orexo US, Inc, Morristown, New
Jersey).
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Clinical Therapeuticsefﬁcacy and tolerability of the higher-bioavailability
BNX sublingual tablet in opioid-dependent patients
were assessed in the Induction, Stabilization, Adher-
ence and Retention Trial. This study compared the
efﬁcacy and tolerability of the higher-bioavailability
BNX sublingual tablet with those of generic bupre-
norphine, and stabilization with higher-bioavailability
BNX sublingual tablet with that of the BNX ﬁlm. To
better reﬂect patients treated in clinical practice, the
study enrolled patients being transitioned from short-
or long-acting opioid use. The primary objective was
to assess the efﬁcacy of the BNX sublingual tablet
formulation, measured as retention in treatment dur-
ing the induction and stabilization phases. Secondary
objectives included the assessment of treatment effects
on opioid withdrawal symptoms and cravings, and
treatment tolerability.
PATIENTS AND METHODS
Study Design
This prospective, multicenter, randomized, parallel-
group, noninferiority trial was conducted at 43 centers
in the United States from August 2013 to April 2014.
A noninferiority design was used because the BNX
sublingual tablet and BNX ﬁlm contain the same
active components, and it would have been considered
unethical to have included a placebo arm. This study
was conducted in accordance with the Declaration of
Helsinki and its subsequent revisions, and in compli-
ance with the International Conference on Harmoni-
sation Good Clinical Practice guideline and all
applicable laws and regulations. The study protocol
was approved by an institutional review board at each
site, and all patients provided written informed con-
sent to participate.
The study comprised an induction phase of 2 days
and a stabilization phase of 20 days, with study visits
scheduled on days 1, 2, 3, 4, 8, 15, and 22. Eligible
opioid-dependent patients were randomly assigned
(1:1) within 14 days after screening to receive induc-
tion with either the higher-bioavailability BNX sub-
lingual tablet or a generic buprenorphine tablet for
2 days. Generic buprenorphine was selected as the
comparator drug for induction in this trial as it was
the only product approved for use as induction
therapy when the study was designed. In addition, it
is currently the only formulation indicated for induc-
tion after both short- and long-acting opioid use.10
Randomization and allocation of treatments were2246made through an Interactive Response Technology
service. The doses on days 1 and 2 were provided in
kits allocated through the Interactive Response
Technology randomization procedure.
On day 3, patients allocated to induction using the
higher-bioavailability BNX sublingual tablet were
continued on the same treatment during the stabiliza-
tion phase, whereas those allocated to induction using
buprenorphine were switched to BNX ﬁlm.
On day 15, patients on BNX sublingual tablets
were switched to BNX ﬁlm, and those receiving BNX
ﬁlm were switched to BNX sublingual tablets. At the
ﬁnal study visit on day 22, patients were offered the
option of continuing in an open-labeled follow-up
study of the higher-bioavailability BNX sublingual
tablet.
Inclusion and Exclusion Criteria
Male or female adults aged 18 to 65 years, in
generally good health, and who met the criteria for
opioid dependence as outlined in the Diagnostic and
Statistical Manual of Mental Disorders, Fourth Edi-
tion, Text Revision (DSM-IV-TR) in the 12 months
before the start of the study were eligible for inclusion
if they agreed to abstain from opioid utilization (other
than study drug) and from the use of other addictive
drugs, and if they demonstrated at least mild with-
drawal symptoms, deﬁned as a score of Z9 on the
Clinical Opiate Withdrawal Scale (COWS) predose on
day 1. Eligibility also required a buprenorphine-
negative urine drug screen and, in female participants,
a negative urine pregnancy test and agreement to use a
reliable method of contraception throughout the
study. Treatment with any opioid prescribed for pain
management was discontinued before induction and
after clearance was obtained from the prescribing
physician.
Patients were excluded from the study if they had
any serious, untreated DSM-IV-TR–deﬁned Axis I
psychiatric comorbidity and/or were considered at
risk for suicide; any clinically signiﬁcant medical
disorder or other condition that might have compro-
mised the participant’s safety or the validity of
the study results; and/or any tongue or other oral
deformity that might have affected the absorption of
the study drugs. Other exclusion criteria were the use
of any of the following: generic buprenorphine mono-
therapy within 90 days before the start of the study;
methadone at a dose of 430 mg/d within the weekVolume 37 Number 10
E.W. Gunderson et al.before the start of the study; any methadone within 30
hours before the initial study treatment; or any
medication or product with strong cytochrome
P-450 3A4 inhibition or induction properties within
14 days before screening.Study Treatment
The study medications included the higher-
bioavailability BNX sublingual tablet (5.7/1.4 or
1.4/0.36 mg), BNX sublingual ﬁlm (8/2 or 2/0.5
mg), and generic buprenorphine sublingual tablets
(8 or 2 mg§). The patients, investigators, and sponsor
were blinded to the treatment assignments; however,
because no buprenorphine-matched placebo was avail-
able, the achievement of an identical appearance of the
study medications was not possible. To maintain
blinding of the investigators to treatment assignments
during induction, study medications were placed in
identical packaging with blinded labels, and induction
therapy was administered with the supervision of a
staff member who was not involved in the clinical
assessments.
On days 1 and 2, patients received a total ﬁxed
dose of higher-bioavailability BNX sublingual tablet
(5.7/1.4 mg and 5.7/1.4 mg or 11.4/2.8 mg, respec-
tively) or generic buprenorphine (8 mg and 8 mg or 16
mg, respectively). On day 3, the start of the stabiliza-
tion phase, the patients receiving generic buprenor-
phine were switched to BNX ﬁlm. Patients were
allowed rescue medication if needed. Dosing during
stabilization was open-labeled; stabilization doses
were titrated to maximal daily doses of 17.1/4.2 mg
and 24/6 mg of the BNX sublingual tablet and BNX
ﬁlm, respectively, on the basis of clinical symptoms.
On day 15, treatments were switched according to a
ﬁxed conversion factor (5.7 to 8 mg) on the basis of
the corresponding dose strengths of the BNX sub-
lingual tablets and BNX ﬁlm.Efficacy and Tolerability Assessments
The co-primary efﬁcacy end points were retention
in treatment on days 3 and 15. Retention in treatment
on day 3 was added as a co-primary efﬁcacy end point
in a protocol amendment for the purpose of assessing
the efﬁcacy and tolerability of the higher-bio-
availability BNX sublingual tablet formulation used§Manufacturer: Roxane Laboratories (Columbus, Ohio).
October 2015for the induction phase of treatment in patients with
opioid dependence. Secondary efﬁcacy end points
included opioid withdrawal symptoms, as assessed
using the COWS (total-score range, 0–48, with a
lesser score being more favorable) and the Subjective
Opiate Withdrawal Scale (SOWS; total-score range,
0–64, with a lesser score being more favorable), and
opioid cravings, as assessed using a visual analog scale
ranging from 0 (“no cravings”) to 100 (“most intense
craving I have ever had”). The staff at each study site
was trained by the study sponsor or monitor on the
proper administration of the scales. These assessments
were performed before dosing on treatment visit days,
and additionally at 0.5, 1.5, 3, and 6 hours after
dosing on day 1.
Tolerability was assessed at all visits using adverse-
events monitoring, including vital signs measurements.
Physical examinations and clinical laboratory tests
were done at screening and at the end of the study.
We report results from all end points through day 15.
Statistical Analysis
The sample-size calculation was made using
nQuery þ nTerim version 2.0 (Statistical Solutions,
Boston, Massachusetts). Assuming a retention rate of
80% on day 15, and assuming that 5% of patients
would not be eligible for the primary efﬁcacy analysis,
a sample size of 708 patients was determined to
have 90% power to ensure that the lower limits of
the 2-tailed 95% CIs of the true between-treatment
differences in retention on days 3 and 15 would
be Z10%.
The primary efﬁcacy analysis of retention in treat-
ment on days 3 and 15 was based on noninferiority
testing, as determined by the primary efﬁcacy end
point of treatment retention, between treatment
groups in the per-protocol population (all randomized
patients who met eligibility criteria and correctly
received the study treatment to which they were
assigned). A priori noninferiority was concluded if
the lower limit of the 95% CI of the difference in
retention rate between treatments was Z10%.
Sensitivity analyses of retention rate and analyses of
all other efﬁcacy end points were performed on data
from all randomized patients who received at least 1
dose of study treatment. For the sensitivity analysis of
retention rate, a logistic regression model was used,
with treatment and center as factors and day 1
predose COWS score as a covariate. Adverse events2247
Clinical Therapeuticswere coded using the Medical Dictionary for Regu-
latory Activities versionZ15.1, and the prevalences of
each were compared between treatment groups using
the χ2 test. Other tolerability parameters were assessed
using descriptive statistics.
RESULTS
Study Population
A total of 758 opioid-dependent patients were
randomly assigned to induction with the higher-
bioavailability BNX sublingual tablet (n ¼ 383) or
generic buprenorphine (n ¼ 375) (Figure 1). The
2 treatment arms were comparable in terms of
patients’ demographic characteristics and baseline
clinical characteristics, including recent methadone
use (Table I). The mean age of the study cohort was
35.6 years; most patients were male (59.6%) and
white (83.1%). The mean duration of opioid
dependence reported was 10.6 years.26 patients discontinued
•  Illness (n=1)
•  Lost to follow-up (n=5)
•  Patient non-compliant (n=5)
•  Patient request (n=6)
•  TEAEs (n=2)
•  Illicit drug use (n=1)
•  Other (n=6)
70 patients discontinued
•  Illness (n=1)
•  IRB request (n=3)
•  Lost to follow-up (n=12)
•  Patient non-compliant (n=20)
•  Patient request (n=6)
•  TEAEs (n=2)
•  Investigational drug use (n=1)
•  Illicit drug use (n=5)
•  Other treatment for opioid 
   dependence (n=2)
•  Other (n=18)
383 patients allocated to 
induction with BNX 
sublingual tablets
357 patients completed 
induction and entered 
open-label treatment with 
BNX sublingual tablets
287 patients switched
treatment at day 15; 
262 patients completed
through day 22
383 patients included in efficacy and safety
populations
329 patients included in PP population
•  54 patients excluded from PP population
758 patients randomi
759 patients sc
Figure 1. Patient disposition. BNX ¼ buprenorphine/na
review board; PP ¼ per protocol; TEAE ¼ tre
2248Efficacy
Retention Rate
In the primary efﬁcacy analysis of data from the
per-protocol population, 309 of 329 patients (93.9%)
in the group that received the higher-bioavailability
BNX sublingual tablet and 302 of 326 patients
(92.6%) in the group that received generic buprenor-
phine were retained in treatment on day 3 (Table II).
On day 15, retention in treatment was achieved in 273
patients (83.0%) in the group that received the BNX
sublingual tablet and in 269 patients (82.5%) in the
BNX ﬁlm group. In both cases, the lower limit of the
95% CI was above the predeﬁned noninferiority limit
of 10%. Thus, in the primary efﬁcacy analysis of
data from the per-protocol population, BNX sublin-
gual tablets were determined as noninferior to bupre-
norphine tablets in the induction phase of treatment,
and as noninferior to BNX ﬁlm in the stabilization
phase of treatment. Comparable results were obtained31 patients discontinued
•  Lost to follow-up (n=7)
•  Patient non-compliant (n=5)
•  Patient request (n=10)
•  TEAEs (n=2)
•  Illicit drug use (n=1)
•  Other (n=6)
65 patients discontinued
•  Illness (n=2)
•  IRB request (n=7)
•  Lost to follow-up (n=18)
•  Patient non-compliant (n=11)
•  Patient request (n=4)
•  Illicit drug use (n=3)
•  Other treatment for opioid 
   dependence (n=1)
•  Other (n=19)
375 patients allocated
to induction with
generic BUP
344 patients completed
induction with generic BUP
and entered open-label
treatment with BNX film
279 patients switched
treatment at day 15
262 completed through
day 22
375 patients included in efficacy and safety
populations
326 patients included in PP population
•  49 patients excluded from PP population
zed and treated
reened
1 patient left site before administration of study medication
loxone; BUP ¼ buprenorphine; IRB ¼ institutional
atment-emergent adverse event.
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Table I. Demographics and baseline clinical characteristics.
Characteristic
BNX Sublingual Tablets
(n ¼ 383)
Generic BUP/BNX Film
(n ¼ 375)
All Patients
(N ¼ 758)
Age, y
Mean (SD) 35.7 (11.26) 35.6 (11.28) 35.6 (11.26)
Range 18–64 18–65 18–65
Sex, no. (%)
Male 216 (56.4) 236 (62.9) 452 (59.6)
Female 167 (43.6) 139 (37.1) 306 (40.4)
Race, no. (%)
White 318 (83.0) 312 (83.2) 630 (83.1)
Black/African American 51 (13.3) 49 (13.1) 100 (13.2)
Other or not recorded 14 (3.7) 14 (3.7) 28 (3.7)
Duration of opioid dependence, mean (SD),
y
10.7 (9.57) 10.5 (9.01) 10.6 (9.29)
Self-report of substance use over previous 30
days, no. (%)*
Heroin 212 (55.5) 199 (53.4) 411 (54.4)
Methadone 51 (13.4) 48 (12.9) 99 (13.1)
Buprenorphine 41 (10.7) 29 (7.8) 70 (9.3)
Other opioids/analgesics 240 (62.8) 235 (63.0) 475 (62.9)
Self-report of substance use in patient's
lifetime, no. (%)*
Heroin 235 (61.8) 236 (63.4) 471 (62.6)
Methadone 127 (33.5) 129 (34.7) 256 (34.1)
Buprenorphine 125 (32.9) 108 (29.0) 233 (31.0)
Other opioids/analgesics 304 (79.8) 288 (77.4) 592 (78.6)
*Percentages based on number of patients with available responses.
Table II. Retention in treatment on days 3 and 15.
Retention, No. (%) Between-Group Difference, %*
BNX Sublingual Tablets Generic BUP Estimate (SE) 95% CI P
Per protocol
Day 3 309/329 (93.9) 302/326 (92.6) 1.3 (1.96) 2.6 to 5.1 0.512
Day 15 273/329 (83.0) 269/326 (82.5) 0.5 (2.95) 5.3 to 6.3 0.875
All patients
Day 3 357/383 (93.2) 344/375 (91.7) 1.5 (1.92) 2.3 to 5.2 0.440
Day 15 287/383 (74.9) 279/375 (74.4) 0.5 (3.16) 5.7 to 6.7 0.866
BNX ¼ buprenorphine/naloxone; BUP ¼ buprenorphine.
*Difference in retention rate for the higher-bioavailability BNX sublingual tablet group minus the generic BUP/BNX ﬁlm group.
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Clinical Therapeuticsin the sensitivity analysis conducted on data from the
entire study cohort (Table II). In the logistics regression
model, the odds ratios of retention in treatment in the
group that received the BNX sublingual tablet compared
with the combined group that received generic
buprenorphine/BNX ﬁlm were 1.10 (95% CI, 0.61–
1.96) on day 3 and 1.02 (95% CI, 0.72–1.45) on day
15. A Kaplan-Meier survival plot for retention in treat-
ment is shown in Figure 2. Retention in treatment did
not differ signiﬁcantly between groups on the basis of
recent methadone use. In the full analysis population,
treatment-retention rates on day 3 in a subgroup of
patients who used methadone 30 days before being
induced with the higher-bioavailability BNX sublingual
tablet or with generic buprenorphine were 80.4% and
79.2%, respectively (between-group difference, 1.2%;
95% CI, –14.6 to 17.1). On day 15, treatment-
retention rates in the subgroup that used methadone 30
days before being induced with the BNX sublingual
tablet or with generic buprenorphine were 68.6% and
64.6%, respectively (between-group difference, 4%;
95% CI, –14.5 to 22.6).10
D1
 pr
e
D1
 0.
5h
D1
 1.
5h
D1
 3h
D1
 6h
D2
 pr
e
D3
 pr
e
D4
 pr
e
D8
 pr
e
D1
5 p
re
Timepoint
Figure 3. Mean time profile of total scores on
the Clinical Opiate Withdrawal Scale
(COWS) (A) and Subjective Opiate
Withdrawal Scale (SOWS) (B), byOpioid Withdrawal Symptoms
Both treatments similarly reduced opioid withdrawal
symptoms, as assessed using COWS and SOWS scores
(Figure 3). The least squares (LS) mean AUC values of
COWS total score from days 1 to 15 were 5.43
and 5.53 in the group that received the BNX
sublingual tablet and the combined group that received
generic buprenorphine/BNX ﬁlm, respectively; the100
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Figure 2. Kaplan-Meier plot of retention in
treatment. BNX ¼ buprenorphine/
naloxone; BUP ¼ buprenorphine.
treatment group. COWS total scores
range from 0–48, with a lesser score
being more favorable. SOWS total
scores range from 0–64, with a
lesser score being more favorable.
BNX ¼ buprenorphine/naloxone;
BUP ¼ buprenorphine.
2250between-group difference in LS mean values was
0.10 (95% CI, 0.54 to 0.34). Similarly, the LS mean
AUC values of SOWS total score were 11.17 and 11.25,
respectively, and the between-group difference in LS
mean values was 0.07 (95% CI, 1.33 to 1.18).
Opioid Cravings
Both treatments similarly reduced opioid cravings
with a time course that paralleled the reduction inVolume 37 Number 10
E.W. Gunderson et al.opioid withdrawal symptoms (Figure 4). On the visual
analog scale for cravings, the LS mean AUC values for
days 1 to 15 were 30.76 in the group that received the
BNX sublingual tablet and 30.07 in the combined
group that received generic buprenorphine/BNX ﬁlm.
The between-group difference in LS mean was 0.70
(95% CI, 2.41 to 3.80).
Doses of Study Treatment
On day 1 of the double-blinded induction phase,
patients received the higher-bioavailability BNX sub-
lingual tablet at a ﬁxed dose of 5.7/1.4 mg or generic
buprenorphine 8 mg. The mean buprenorphine doses
prescribed on day 3 were 10.9 and 14.6 mg in the
groups that received the BNX sublingual tablet and
BNX ﬁlm, respectively. On day 15, the mean pre-
scribed buprenorphine doses were 10.8 and 15.9 mg
in the group that received the BNX sublingual tablet
and BNX ﬁlm, respectively.
Tolerability
The prevalences of treatment-related adverse events did
not differ signiﬁcantly between treatment groups (Table
III). In the induction phase (days 1 and 2), 61 patients
(15.9%) in the group that received the higher-
bioavailability BNX sublingual tablet and 55 patients
(14.7%) in the group that received generic buprenorphine60
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Figure 4. Mean time profile of visual analog
scale (VAS) for opioid craving (ran-
ging from 0 ["no cravings"] to 100
["most intense craving I have ever
had"]). BNX ¼ buprenorphine/nalox-
one; BUP ¼ buprenorphine.
October 2015reported 1 or more treatment-related adverse events (P ¼
0.63). The most commonly reported adverse events were
headache, nausea, and vomiting. In the open-label stabi-
lization phase (days 3–15), the proportions of patients
reporting treatment-related adverse events in the groups
that received the BNX sublingual tablet and BNX ﬁlm
were 11.8% and 10.8%, respectively (P ¼ 0.67). The
most commonly reported adverse events (all patients)
were constipation (3.1%) and headache (1.7%). There
were no treatment-related serious adverse events reported
during either period. Four patients discontinued study
treatment due to treatment-related adverse events during
induction generic buprenorphine group: moderate nausea
and vomiting [n¼ 1]; moderate diaphoresis [n¼ 1]; BNX
sublingual tablet group: moderate ﬂushed face and torso,
moderate vomiting, and mild stomach cramps [n ¼ 1];
moderate nausea and vomiting [n ¼ 1]. Two patients in
the group that received the BNX sublingual tablet in the
open-labeled phase discontinued study treatment due to
treatment-related adverse events (moderate lethargic, vom-
iting, abdominal cramping, and no bowel bovement [n ¼
1]; moderate worsening of dizziness, mild nausea and
fatigue [n ¼ 1]).
DISCUSSION
The ﬁndings from this study, notable for its large-scale
patient population, support the clinical efﬁcacy and
tolerability of a higher-bioavailability BNX sublingual
tablet formulation during initiation of buprenorphine
maintenance treatment of opioid dependence. Speciﬁ-
cally, the efﬁcacy of the higher-bioavailability BNX
sublingual tablet during induction was comparable to
that of generic buprenorphine, and the efﬁcacy of the
BNX sublingual tablet during early stabilization was
comparable to that of BNX ﬁlm. These ﬁndings were
consistent when assessed by treatment retention and by
reductions in withdrawal symptoms and opioid crav-
ings. Opioid withdrawal symptoms and craving were
nearly eliminated by the end of the stabilization period
with the use of the higher-bioavailability BNX sub-
lingual tablet or BNX ﬁlm, consistent with treatment
goals during the early phases of medication-assisted
treatment18 and with previously reported ﬁndings
during induction with BNX ﬁlm.6 Together,
treatment retention and the reduction of clinical
symptoms are important factors in the stabilization of
patients and in the prevention of illicit opioid use.
Generic buprenorphine is currently the only for-
mulation indicated for the induction of maintenance2251
Table III. Prevalence of treatment-related adverse events reported in 41% of patients. Data are given as
number (%) of patients.
MedDRA Preferred Term BNX Sublingual Tablets Generic BUP/BNX Film All Patients
Double-blind period (days 1 and 2) n ¼ 383 n ¼ 375 N ¼ 758
Any 61 (15.9) 55 (14.7) 116 (15.3)
Headache 20 (5.2) 19 (5.1) 39 (5.1)
Vomiting 12 (3.1) 11 (2.9) 23 (3.0)
Nausea 8 (2.1) 15 (4.0) 23 (3.0)
Dry mouth 8 (2.1) 2 (0.5) 10 (1.3)
Somnolence 6 (1.6) 2 (0.5) 8 (1.1)
Insomnia 5 (1.3) 4 (1.1) 9 (1.2)
Constipation 4 (1.0) 3 (0.8) 7 (0.9)
Open-label period (days 3–15) n ¼ 357 n ¼ 344 N ¼ 701
Any 42 (11.8) 37 (10.8) 79 (11.3)
Constipation 10 (2.8) 12 (3.5) 22 (3.1)
Headache 5 (1.4) 7 (2.0) 12 (1.7)
Nausea 5 (1.4) 1 (0.3) 6 (0.9)
Somnolence 5 (1.4) 1 (0.3) 6 (0.9)
Vomiting 4 (1.1) 2 (0.6) 6 (0.9)
BNX ¼ buprenorphine/naloxone; BUP ¼ buprenorphine; MedDRA ¼ Medical Dictionary for Regulatory Activities.
Clinical Therapeuticstreatment both in patients dependent on short-acting
opioids and in those dependent on long-acting
opioids10; however, the ﬁndings from the present
study suggest that the higher-bioavailability BNX
sublingual tablet formulation may be appropriate for
induction therapy in patients dependent on short- or
long-acting opioids, including methadone. Between-
group differences in treatment retention on days 3 and
15 in the subgroup of patients who had used meth-
adone within the 30 days before treatment induction
were small and associated with tightly overlapping
95% CIs. When interpreting these data, it is important
to note that only a small number of patients included
in the study had a history of methadone use in the 30
days before induction (n ¼ 99); therefore, the study
was underpowered to detect small differences in
treatment retention among these patients.
No unexpected tolerability issues were identiﬁed
during this study. The safety proﬁle of the higher-
bioavailability BNX sublingual tablet formulation was
similar to that of generic buprenorphine during the
blinded induction phase and similar to that of BNX
ﬁlm during the open-labeled stabilization phase.
Moreover, the ﬁndings on the tolerability of the2252higher-bioavailability BNX sublingual tablet were
comparable to those reported in a previous study of
this proprietary formulation19 and are aligned with
the safety proﬁles of both buprenorphine sublingual
tablets20,21 and BNX sublingual ﬁlm.6
In this study, the investigators were permitted to
titrate the doses of the BNX sublingual tablet and
BNX ﬁlm. Although the BNX sublingual tablet for-
mulation retains the 4:1 ratio of buprenorphine to
naloxone, it contains amounts of buprenorphine and
naloxone (5.7/1.4 mg) that are less than those in the
corresponding ﬁlm formulation (8/2 mg) due to
enhanced transmucosal absorption of the active in-
gredients.17 Consistent with the pharmacokinetic
properties of the product, comparable efﬁcacy of the
2 formulations was achieved with doses of
buprenorphine and naloxone that are less in the
BNX sublingual tablet than in the BNX ﬁlm. The
mean buprenorphine doses measured on days 3 and
15 were 26% and 32% less, respectively, in the group
that received the BNX sublingual tablet compared
with those in the group that received the BNX ﬁlm.
The extent of the public health beneﬁts due to the
lesser buprenorphine dose in the higher-bioavailabilityVolume 37 Number 10
E.W. Gunderson et al.BNX sublingual tablet formulation may be related to
the product being less attractive for misuse or diver-
sion; however, this concept remains to be determined.
The availability of higher dose strengths of this BNX
sublingual tablet (8.6/2.1 and 11.4/2.9 mg) might
simplify dosing and allow patients to be treated with
fewer tablets daily. In addition, less buprenorphine in
this formulation may result in a decreased preference
for the BNX sublingual tablet by injection-drug users.
However, further research is necessary for determin-
ing whether the higher-bioavailability BNX sublingual
tablet reduces misuse and diversion compared with
such reductions with use of other medications used for
treating opioid dependence.
Strengths of the clinical study described herein
included the use of a noninferiority, prospective design;
a large-scale population of opioid-dependent patients
transitioning from the use of a broad array of short- and
long-acting opioids; and standardized measures of treat-
ment retention, opioid withdrawal symptoms, and
opioid craving. This study also had several limitations.
Although the investigators and patients were blinded to
induction-therapy assignments, patients previously
treated with buprenorphine-containing products may
have distinguished the treatment assignment based on
differences in aftertaste and mouth-feel; however, such
recognition might be a disadvantage for the higher-
bioavailability formulation under investigation given the
likely greater familiarity with the higher unit dose
products. For example, the ﬁndings from the subjective
measures used during the open-label phase might have
been affected by patients’ bias toward BNX ﬁlm, a well-
known opioid-dependence treatment product. In addi-
tion, this study was conducted at selected clinical
research sites, and the ﬁndings might not be general-
izable to all ofﬁce-based practices. For example, reten-
tion may be greater in patients treated at dedicated
treatment centers with integrated, specialized counseling
and other supportive services. Finally, the study was not
speciﬁcally designed or statistically powered to establish
the efﬁcacy of the higher-bioavailability BNX sublingual
tablet formulation in patients transferring from long-
acting opioid use. Notably, the subgroup with recent
methadone use before study entry had reduced
treatment-retention rates of 10% to 15% compared
with the entire patient population. Similar reductions in
treatment-retention rates were observed in both treat-
ment arms in this subgroup. The challenge of bupre-
norphine induction among patients transitioning fromOctober 2015methadone has been previously reported,12,13,22 and
further studies are needed for elucidating treatment
protocols regarding induction in patients transitioning
from the use of long-acting opioids such as methadone.
CONCLUSIONS
Noninferiority was established between the higher-
bioavailability sublingual BNX tablet formulation and
the generic buprenorphine tablet formulation during
the induction phase and between the higher-
bioavailability BNX tablet and BNX ﬁlm during the
early stabilization phase of treatment among these
patients dependent on short- or long-acting opioids.
Treatment-retention rates on day 3 (after induction)
and on day 15 (after stabilization) were similar between
treatment groups, as were the decreases in withdrawal
symptoms and opioid cravings. Comparable efﬁcacy
between treatments was achieved despite the admin-
istration of less buprenorphine in the BNX sublingual
tablet compared with generic buprenorphine or BNX
ﬁlm, which is consistent with the enhanced trans-
mucosal absorption of active ingredients from the
BNX sublingual tablet formulation. The ﬁndings from
this study suggest that the higher-bioavailability BNX
sublingual tablet formulation is an efﬁcacious and well-
tolerated option for induction and early stabilization
treatment of opioid dependence. Overall, the ﬁndings
from this study provide important information for
guiding informed treatment decisions by prescribers
and patients during the induction and maintenance
phases of treatment, as well as potentially to lessen the
public health epidemic of opioid dependence.
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